Brixton Biosciences Raises $33M in Series B Funding to Advance Novel Pain Relief Therapy Technology - Next Digital Health

Brixton Biosciences, a clinical-stage life science startup focusing on developing therapies for acute and chronic pain relief, has raised $33 million in series B funding to pursue pivotal clinical studies on the treatment of osteoarthritis-related knee pain and extend its Neural Ice™ application. The new round, led by Schooner Capital, included significant contributions from SV
read more..